Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Lucid Diagnostics Inc. (NASDAQ: LUCD), a cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (NASDAQ: PAVM, PAVMZ), announced its participation in the 22nd Annual Needham Healthcare Conference. Executives Dr. Lishan Aklog and Dennis McGrath will present on April 20, 2023, at 11:00 AM ET. Lucid focuses on patients with gastroesophageal reflux disease (GERD), a condition that increases the risk of esophageal precancer and cancer. Their flagship product, the EsoGuard® Esophageal DNA Test, is a non-invasive tool designed for early cancer detection in at-risk patients. For those interested in meeting with management during the conference, inquiries can be directed to Needham representatives. For more details, visit luciddx.com.

NEW YORK, April 17, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Dr. Lishan Aklog, Chairman and Chief Executive Officer; and Dennis McGrath, Chief Financial Officer will present at the 22^nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 11:00 AM ET.

Institutional investors interested in meeting with management during the conference may reach out to their Needham representative.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.  

For more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-present-at-22nd-annual-needham-virtual-healthcare-conference-301799619.html

SOURCE Lucid Diagnostics

FAQ

When will Lucid Diagnostics present at the Needham Healthcare Conference?

Lucid Diagnostics will present on April 20, 2023, at 11:00 AM ET.

What is the focus of Lucid Diagnostics?

Lucid Diagnostics focuses on cancer prevention, particularly for patients with gastroesophageal reflux disease (GERD) at risk of esophageal cancer.

What is the EsoGuard® Esophageal DNA Test?

The EsoGuard® Esophageal DNA Test is a non-invasive diagnostic tool for early detection of esophageal precancer in at-risk GERD patients.

Who are the key executives presenting for Lucid Diagnostics?

Dr. Lishan Aklog and Dennis McGrath will present for Lucid Diagnostics.

What companies are associated with Lucid Diagnostics?

Lucid Diagnostics is a majority-owned subsidiary of PAVmed Inc. (NASDAQ: PAVM, PAVMZ).